Vabysmo
E822409
angiogenesis inhibitor
bispecific monoclonal antibody
brand name drug
ophthalmic drug
pharmaceutical drug
Vabysmo is the brand name for faricimab, an injectable eye medication used to treat retinal diseases such as neovascular (wet) age-related macular degeneration and diabetic macular edema.
Statements (51)
| Predicate | Object |
|---|---|
| instanceOf |
angiogenesis inhibitor
ⓘ
bispecific monoclonal antibody ⓘ brand name drug ⓘ ophthalmic drug ⓘ pharmaceutical drug ⓘ |
| adverseEffect |
conjunctival hemorrhage
ⓘ
eye pain ⓘ increased intraocular pressure ⓘ vitreous floaters ⓘ |
| approvalYear | 2022 ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIn |
European Union
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| belongsToClass |
anti-VEGF agents
ⓘ
anti-angiopoietin agents ⓘ |
| clinicalTrial |
LUCERNE
NERFINISHED
ⓘ
RHINE ⓘ TENAYA NERFINISHED ⓘ YOSEMITE NERFINISHED ⓘ |
| comparedWith | aflibercept NERFINISHED ⓘ |
| contraindication |
active intraocular inflammation
ⓘ
ocular or periocular infection ⓘ |
| developedBy |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| hasATCCode | S01LA07 ⓘ |
| hasDosageForm | solution for intravitreal injection ⓘ |
| hasDosingInterval |
every 4 weeks (loading phase)
ⓘ
up to every 16 weeks (maintenance phase, label-dependent) ⓘ |
| hasGenericName | faricimab NERFINISHED ⓘ |
| hasINN | faricimab NERFINISHED ⓘ |
| hasMechanismOfAction |
inhibits VEGF-A and Ang-2 signaling pathways
ⓘ
reduces pathological ocular neovascularization ⓘ stabilizes retinal vasculature ⓘ |
| indicationPopulation | adults ⓘ |
| legalStatus | prescription only ⓘ |
| marketedBy |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| routeOfAdministration | intravitreal injection ⓘ |
| seriousAdverseEffect |
endophthalmitis
ⓘ
retinal detachment ⓘ |
| targets |
VEGF-A
NERFINISHED
ⓘ
angiopoietin-2 ⓘ vascular endothelial growth factor A ⓘ |
| therapeuticArea | ophthalmology ⓘ |
| treatsSymptom |
vision impairment due to diabetic macular edema
ⓘ
vision loss due to wet age-related macular degeneration ⓘ |
| usedFor |
diabetic macular edema
ⓘ
macular edema following retinal vein occlusion ⓘ neovascular age-related macular degeneration ⓘ retinal vein occlusion ⓘ wet age-related macular degeneration ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.